Implementation and obstacles of pharmacogenetics in clinical practice: An international survey

Abstract

Aims Eight years ago, a paper‐based survey was administered during the World Pharma 2010 meeting, asking about the challenges of implementing pharmacogenetics (PGx) in clinical practice. The data collected at the time gave an idea about the progress of this implementation and what still needs to be done. Since then, although there have been major initiatives to push PGx forward, PGx clinical implementation may still be facing different challenges in different parts of the world. Our aim was therefore to distribute a follow‐up international survey in electronic format to elucidate an overview on the current stage of implementation, acceptance and challenges of PGx in academic institutions around the world. Methods This is an online anonymous LimeSurvey‐based study launched on 11 November 2018. Survey questions were adapted from the initially published manuscript in 2010. An extensive web search for worldwide scientists potentially involved in PGx research resulted in a total of 1973 names. Countries were grouped based on the Human Development Index. Results There were 204 respondents from 43 countries. Despite the wide availability of PGx tests, the consistently positive attitude towards their applications and advances in the field, progress of the clinical implementation of PGx still faces many challenges all around the globe. Conclusions Clinical implementation of PGx started over a decade ago but there is a gap in progress around the globe and discrepancies between the challenges reported by different countries, despite some challenges being universal. Further studies on ways to overcome these challenges are warranted.

A Tutorial for Pharmacogenomics Implementation Through End‐to‐End Clinical Decision Support Based on Ten Years of Experience from PREDICT

“…Surveys of practicing clinicians and their patients indicate a high level of interest in implementing PGx testing 11–14 . However, clinicians have also described specific barriers that need to be addressed to support improved workflow and actionability 15 .…”

“…Surveys of practicing clinicians and their patients indicate a high level of interest in implementing PGx testing. [11][12][13][14] However, clinicians have also described specific barriers that need to be addressed to support improved workflow and actionability. 15 One such critical barrier is the lack of provider familiarity with standard PGx result reporting, including the star allele nomenclature, phenotype interpretations, and the associated CPIC or US Food and Drug Administration (FDA) supporting information.…”

Pharmacogenetics in Psychiatry: Perceived Value and Opinions in a Chilean Sample of Practitioners

“…To bridge the gap between current and future appropriate use, local research and implementation strategies are needed. Understanding the scope and problems of PGx implementation can also benefit from collaboration throughout Latin America since the similar challenges are shared by other countries in the region (Abou Diwan et al, 2019).…”

Pharmacogenomic information from CPIC and DPWG guidelines and its application on drug labels

“…However, there are several huddles for implementing PGx in precision medicine. Cost of genetic tests and reimbursements are common problems facing implementation of PGx in clinical practice around the world [9]. Moreover, lack of education and unawareness of PGx by physicians and pharmacists who actually work with drugs are other obstacles [10,11].…”